Visudyne Medicare Settlement: CMS Cmte To Review Occult Lesion Data

CMS' Medicare Coverage Advisory Committee will review initial data from QLT's Phase III trial of Visudyne (verteporfin) for age-related macular degeneration patients with occult lesions